Optimization of the efflux ratio and permeability of covalent irreversible BTK inhibitors
Graphical abstract
Section snippets
Acknowledgments
We appreciate the valuable suggestions from our colleagues Dr. Yanping Wang and Esther Cleary.
References (33)
- et al.
Btk function in B cell development and response
Semin Immunol
(1998) - et al.
Targeting Btk with ibrutinib in relapsed/refractory marginal zone
Blood
(2017) - et al.
Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling
Blood
(2014) - et al.
Ibrutinib-associated pityriasis rosea–like rash
JAAD Case Rep.
(2018) - et al.
Second-generation inhibitors of Bruton tyrosine kinase
J. Hematol. Oncol.
(2016) - et al.
Intramolecular hydrogen bonding to improve membrane permeability and absorption in beyond rule of five chemical space
Med. Chem. Comm.
(2011) - ...
- et al.
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia
N Engl J Med
(2014) Regulation of B lymphocyte development and activation by Bruton’s tyrosine kinase
Immunol Res
(2001)
The role of Bruton’s tyrosine kinase in B-cell development and function: a genetic perspective
Immunol Rev
(2000)
Bruton’s tyrosine kinase is involved in innate and adaptive immunity
Histol Histopathol
(2005)
Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis
Nat Chem Biol
(2011)
B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies
Int Rev Immunol
(2013)
Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders
Expert Opin Invest Drugs
(2012)
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies
J Clin Oncol
(2013)
Cited by (0)
© 2018 Elsevier Ltd. All rights reserved.